Share on StockTwits
 

RTI Biologics (NASDAQ:RTIX) posted its quarterly earnings results on Thursday. The company reported ($0.01) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.01), AnalystRatingsNetwork reports. The company had revenue of $60.50 million for the quarter, compared to the consensus estimate of $59.20 million.

On a related note, analysts at Zacks upgraded shares of RTI Biologics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, December 31st. They now have a $3.50 price target on the stock.

RTI Biologics (NASDAQ:RTIX) opened at 3.26 on Thursday. RTI Biologics has a one year low of $2.77 and a one year high of $4.53. The stock has a 50-day moving average of $3.28 and a 200-day moving average of $3.37. The company’s market cap is $183.3 million.

RTI Biologics, Inc process human musculoskeletal and other tissue. It also processes bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE and TUTOPLAST sterilization processes, for distribution to hospitals and surgeons.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.